Energy Transfer: Pointless To Fight Against The Market (Rating Downgrade)
44.43K Followers
JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst.
» Read more about: Energy Transfer: Pointless To Fight Against The Market (Rating Downgrade) »
Read MoreIs the stock market open on Monday for Columbus Day 2025?
Columbus Day 2025, which is also known as Indigenous Peoples’ Day in some communities, is celebrated on Monday, Oct. 13.
Although many businesses and services, such as banks and the U.S. Postal Service, remain closed for the holiday, the stock market is an exception to the rule.
» Read more about: Is the stock market open on Monday for Columbus Day 2025? »
Read MoreA tax-refund surge is coming, JPMorgan strategist says — and it’ll shift US economy like a new round of stimulus checks
There’s a fresh wave of tax refunds coming for Americans in 2026.
Trump’s quest to fire Lisa Cook from the Federal Reserve is now with the Supreme Court
President Donald Trump’s bid to fire Lisa Cook from the Federal Reserve is now at the Supreme Court. It’s the latest legal test of Trump’s power in his second term, and it carries great practical implications for the economy.
In an application Thursday,
TSLA, PLTR and SMCI Forecast – Tech Stocks Rally in Premarket Trading on Monday
Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties,
» Read more about: TSLA, PLTR and SMCI Forecast – Tech Stocks Rally in Premarket Trading on Monday »
Read MoreThe Burst
1 Under-the-Radar Pharma Stock with 90% Upside?
Billionaire Stanley Druckenmiller has been making large changes to his portfolio recently, leaving retail investors struggling to keep up with what the famous stock picker is thinking.
One of the smaller holdings in Druckenmiller’s portfolio that makes for interesting examination is ARS Pharmaceuticals (NASDAQ:SPRY).
Druckenmiller’s 536,900 shares of SPRY are currently valued at around $7 million.
» Read more about: 1 Under-the-Radar Pharma Stock with 90% Upside? »
Read MoreThe Ivy
2 Stocks To Count On For Next Decade
Trade wars and tariffs are taking their toll but that also translates to opportunity among some quality names that have taken a hit, such as Dutch Bros. Even after a market dip, the share price is still up 14% this year, far outpacing the broader market.
The relative outperformance stems from Dutch Bros’
» Read more about: 2 Stocks To Count On For Next Decade »
Read MoreThe Spotlight
1 FinTech Firm with 30.6% Upside
When you study business for a while, certain metrics just turn out to be much more important than others. The cost to acquire customers is a key focus for many new business owners but their retention is what those who have been around the block focus on.
If you can acquire customers at the same price as the competition but sell them into many other products and services,